Trials / Terminated
TerminatedNCT04473027
BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs
BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD Trial)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 3 (actual)
- Sponsor
- University Hospital, Ghent · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
BLOOD is an investigator-initiated, multicenter, prospective biomarker study in patients with advanced melanoma treated with anti-PD-1 monotherapy in the first-line setting. The "studied products" will be administered and managed within routine medical care in Belgium. The overall goal is (i) to investigate biomarkers for anti-PD-1 monotherapy and (ii) to gather evidence on real-life use of anti-PD-1 monotherapy in melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Blood sample collection | Whole venous blood of participants will be collected in EDTA tubes (max. 10 mL) at baseline, before start of first immunotherapy round. The Belgian Red Cross will perform serological blood group diagnostics, and molecular RBC typing. |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2021-04-22
- Completion
- 2021-04-22
- First posted
- 2020-07-16
- Last updated
- 2021-05-10
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04473027. Inclusion in this directory is not an endorsement.